Semi-annual Report for 2026
Filed with SSE · · 149 pages · Chinese
Jiangsu Kanion Pharmaceutical Co. Ltd. on 6ix
Earlier from Jiangsu Kanion Pharmaceutical
- Announcement on Receipt of the Clinical Trial Approval Notice for Qihuang Zhengqi Granules
- Announcement on Initially Repurchasing Shares through Call Auction
- Announcement on Inclusion of Certain Pharmaceutical Products of the Company in the National Essential Medicines List
- Announcement on Progress in Repurchasing Shares through Call Auction
- Announcement on Cancellation of Repurchased Shares and Notification to Creditors
Later from Jiangsu Kanion Pharmaceutical
- (600557)"Jiangsu Kanion Pharmaceutical Co., Ltd."Announcement on Progress in Repurchasing Shares through Call Auction
- (600557)"Jiangsu Kanion Pharmaceutical Co., Ltd."Announcement on Departure of Senior Executive
- (600557)"Jiangsu Kanion Pharmaceutical Co., Ltd."Announcement on Receipt of the Clinical Trial Approval Notice for Shiwei Anchang Granules
- (600557)"Jiangsu Kanion Pharmaceutical Co., Ltd."Announcement on Key Operating Data for the First Three Quarters of 2026
- (600557)"Jiangsu Kanion Pharmaceutical Co., Ltd."Report for Q3 2026
Follow Jiangsu Kanion Pharmaceutical into a list and get an email when it puts out news.
Follow Jiangsu Kanion Pharmaceutical